Natixis Natera, Inc. Transaction History

Natixis

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$85.28 - $112.6 $32,918 - $43,463	-386 Reduced 4.66%	7,897 $855,000
Q1 2024 May 13, 2024	BUY	$59.21 - $92.9 $490,436 - $769,490	8,283 New	8,283 $757,000
Q2 2022 Aug 12, 2022	SELL	$28.13 - $44.54 $486,649 - $770,542	-17,300 Reduced 51.95%	16,000 $567,000
Q1 2022 May 13, 2022	BUY	$30.32 - $91.33 $1.01 Million - $3.04 Million	33,300 New	33,300 $1.36 Million
Q4 2021 Feb 14, 2022	SELL	$86.26 - $119.0 $806,703 - $1.11 Million	-9,352 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$100.17 - $126.36 $685,964 - $865,313	-6,848 Reduced 42.27%	9,352 $1.04 Million
Q2 2021 Aug 13, 2021	BUY	$86.05 - $119.72 $490,485 - $682,404	5,700 Added 54.29%	16,200 $1.84 Million
Q1 2021 May 14, 2021	SELL	$91.47 - $124.36 $521,379 - $708,852	-5,700 Reduced 35.19%	10,500 $1.07 Million
Q4 2020 Feb 12, 2021	BUY	$66.66 - $111.74 $1.08 Million - $1.81 Million	16,200 New	16,200 $1.61 Million

528

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.3B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.